Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H16O |
Molecular Weight | 164.2441 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(O)C1=CC=CC=C1
InChI
InChIKey=OVGORFFCBUIFIA-UHFFFAOYSA-N
InChI=1S/C11H16O/c1-2-3-9-11(12)10-7-5-4-6-8-10/h4-8,11-12H,2-3,9H2,1H3
DescriptionSources: http://www.noventis.cz/febichol-gp
Sources: http://www.noventis.cz/febichol-gp
Fenipentol is a choleretic agent indicated for the treatment of chronic liver disease and bile duct disease. The drug is sold without prescription.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Secretion of bile Sources: http://www.ncbi.nlm.nih.gov/pubmed/13924674 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FEBICHOL Approved UseFebichol capsules are to be used by adult patients to treat digestive problems in chronic (long-term) liver disease and bile duct disease (disorders of gall bladder activity, chronic cholecystitis, chronic development of gall bladder stones, chronic liver disease associated with digestive symptoms caused by impairment or disorder of biliary tree) and conditions after surgical removal of gall bladder or after hepatitis. |
|||
Sources: http://www.noventis.cz/febichol-gp |
Primary | FEBICHOL Approved UseFebichol capsules are to be used by adult patients to treat digestive problems in chronic (long-term) liver disease and bile duct disease (disorders of gall bladder activity, chronic cholecystitis, chronic development of gall bladder stones, chronic liver disease associated with digestive symptoms caused by impairment or disorder of biliary tree) and conditions after surgical removal of gall bladder or after hepatitis. |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and antioxidant properties of some indole ethylamine derivatives as melatonin analogs. | 2005 Sep |
|
Running speed in mammals increases with muscle n-6 polyunsaturated fatty acid content. | 2006 Dec 20 |
|
Dietary exposure of children and teenagers to benzoates, sulphites, butylhydroxyanisol (BHA) and butylhydroxytoluen (BHT) in Beirut (Lebanon). | 2007 Feb |
|
Improved and efficient synthesis of chiral N,P-ligands via cyclic sulfamidates for asymmetric addition of butyllithium to benzaldehyde. | 2007 Sep 13 |
|
Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism. | 2008 Nov 28 |
|
Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. | 2010 Dec |
|
Contribution of dietary intakes of antioxidants to homocysteine-induced low density lipoprotein (LDL) oxidation in atherosclerotic patients. | 2010 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.noventis.cz/febichol-gp
Standard dosage for adults and youths over 15 years of age is 2 capsules (each capsule of contains 100 mg of active ingredient fenipentol) three times a day (always immediately before meals).
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66913
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
583-03-9
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
8478
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104321
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
C013992
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
C65652
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
21632-19-9
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
SUPERSEDED | |||
|
3338
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
X3FZE77O60
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
136264-41-0
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
SUPERSEDED | |||
|
SUB07567MIG
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
3413
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
1151
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
209-493-9
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
24846
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID4046818
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
100000081296
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | |||
|
m5276
Created by
admin on Fri Dec 15 15:54:50 GMT 2023 , Edited by admin on Fri Dec 15 15:54:50 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY